Educating Patients With Advanced RCC on Side Effects of Available Combination Therapies

Opinion
Video

Dr. Hutson explains approaches to educating patients on potential side effects of immunotherapy combinations for kidney cancer, empowering them to manage side effects and maintain quality of life while getting clinical benefit from these life-extending therapies.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.